Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):521-7. doi: 10.1007/s00259-003-1381-0. Epub 2003 Dec 10.


We have previously shown a correlation between the absence of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake and overexpression of the anti-apoptotic protein Bcl-2 in human breast carcinoma. To establish a direct cause-effect relationship between Bcl-2 overexpression and reduced (99m)Tc-MIBI uptake, MCF-7 and T47D breast cancer cell lines were stably transfected with the human Bcl-2 gene to increase intracellular protein levels and tested for (99m)Tc-MIBI uptake. All clones overexpressing Bcl-2 showed a dramatic reduction of (99m)Tc-MIBI uptake as compared with mock transfected control cells. Tracer uptake was promptly and partially restored by induction of apoptosis with staurosporine treatment. After 4.5 h of staurosporine treatment, a tenfold increase in (99m)Tc-MIBI uptake was observed in treated as compared with untreated Bcl-2 overexpressing cells. Our findings provide a rational basis for the development of an in vivo test to detect Bcl-2 overexpression in human tumours.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • Cloning, Molecular / methods
  • Humans
  • Metabolic Clearance Rate
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism*
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics
  • Recombinant Proteins / metabolism
  • Staurosporine / pharmacology*
  • Technetium Tc 99m Sestamibi / pharmacokinetics*
  • Transfection


  • Proto-Oncogene Proteins c-bcl-2
  • Radiopharmaceuticals
  • Recombinant Proteins
  • Technetium Tc 99m Sestamibi
  • Staurosporine